268 related articles for article (PubMed ID: 26612480)
21. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
Kondagunta GV; Bacik J; Donadio A; Bajorin D; Marion S; Sheinfeld J; Bosl GJ; Motzer RJ
J Clin Oncol; 2005 Sep; 23(27):6549-55. PubMed ID: 16170162
[TBL] [Abstract][Full Text] [Related]
22. Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors.
Nakamura T; Ueda T; Oishi M; Nakanishi H; Fujihara A; Naya Y; Hongo F; Kamoi K; Okihara K; Miki T
Int J Urol; 2015 Mar; 22(3):288-93. PubMed ID: 25393104
[TBL] [Abstract][Full Text] [Related]
23. Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies.
Beer TM; Tangen CM; Nichols CR; Margolin KA; Dreicer R; Stephenson WT; Quinn DI; Raghavan D; Crawford ED
Cancer; 2006 Jun; 106(12):2624-9. PubMed ID: 16688776
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT.
Einhorn LH; Brames MJ; Heinrich MC; Corless CL; Madani A
Am J Clin Oncol; 2006 Feb; 29(1):12-3. PubMed ID: 16462496
[TBL] [Abstract][Full Text] [Related]
25. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.
Powles T; Shamash J; Berney D; Oliver RT
Br J Cancer; 2003 Sep; 89(6):1140-1; author reply 1141-2. PubMed ID: 12966438
[No Abstract] [Full Text] [Related]
26. High-Dose Chemotherapy in a Late Relapse, Platinum-Refractory Nonseminomatous Germ Cell Tumor.
Connell BJ; Patel MJ; Tretter CG
Clin Genitourin Cancer; 2016 Aug; 14(4):e441-3. PubMed ID: 27055370
[No Abstract] [Full Text] [Related]
27. Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor.
Kurobe M; Kawai K; Oikawa T; Ichioka D; Kandori S; Takaoka E; Kojima T; Joraku A; Suetomi T; Miyazaki J; Nishiyama H
J Cancer Res Clin Oncol; 2015 Jan; 141(1):127-33. PubMed ID: 25062721
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.
Adra N; Einhorn LH; Althouse SK; Ammakkanavar NR; Musapatika D; Albany C; Vaughn D; Hanna NH
Ann Oncol; 2018 Jan; 29(1):209-214. PubMed ID: 29045540
[TBL] [Abstract][Full Text] [Related]
29. Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments.
Oing C; Seidel C; von Amsberg G; Oechsle K; Bokemeyer C
Expert Opin Pharmacother; 2016; 17(4):545-60. PubMed ID: 26630452
[TBL] [Abstract][Full Text] [Related]
30. A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma.
Padrnos L; Ernst B; Dueck AC; Kosiorek HE; Ginos BF; Toro A; Johnston PB; Habermann TM; Leis JF; Mikhael JR; Nowakowski GS; Colgan J; Porrata L; Ansell SM; Witzig TE; Reeder C
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):664-672.e2. PubMed ID: 30104176
[TBL] [Abstract][Full Text] [Related]
31. Survival after an antiangiogenetic therapy and surgery in a wide spread growing teratoma originating from a testicular mixed malignant germ cell tumor.
Calaminus G; Schneider DT; Weissbach L; Schönberger S; Okpanyi V; Leuschner I; Poremba C; Göbel U
Klin Padiatr; 2009; 221(3):136-40. PubMed ID: 19437360
[TBL] [Abstract][Full Text] [Related]
32. Investigational targeted therapies for the treatment of testicular germ cell tumors.
Oing C; Kollmannsberger C; Oechsle K; Bokemeyer C
Expert Opin Investig Drugs; 2016 Sep; 25(9):1033-43. PubMed ID: 27286362
[TBL] [Abstract][Full Text] [Related]
33. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
34. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.
Mueller T; Mueller LP; Luetzkendorf J; Voigt W; Simon H; Schmoll HJ
Tumour Biol; 2006; 27(2):71-83. PubMed ID: 16557044
[TBL] [Abstract][Full Text] [Related]
35. Why doesn't high-dose chemotherapy improve survival, as was expected, in advanced or relapsed germ cell tumours?
Pizzocaro G; Guarneri A
Eur Urol; 2009 Jul; 56(1):46-7. PubMed ID: 19303203
[No Abstract] [Full Text] [Related]
36. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.
Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ
Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464
[TBL] [Abstract][Full Text] [Related]
37. [Treatment outcome of children and adolescents with germ cell tumor after combined therapy---a report of 44 cases].
Sun XF; Yang QY; Zhen ZJ; Xia Y; Huang ZH; Ling JY
Ai Zheng; 2006 Dec; 25(12):1529-32. PubMed ID: 17166380
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
[TBL] [Abstract][Full Text] [Related]
39. Current Management of Refractory Germ Cell Tumors.
Abughanimeh O; Teply BA
Curr Oncol Rep; 2021 Jul; 23(9):101. PubMed ID: 34269906
[TBL] [Abstract][Full Text] [Related]
40. Testicular germ cell tumors in adolescents - results of the protocol MAHO 98 and the identification of good risk patients.
Göbel U; Calaminus G; Haas R; Teske C; Schönberger S; Schneider DT; Leuschner I; Harms D
Klin Padiatr; 2014 Nov; 226(6-7):316-22. PubMed ID: 25431864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
